Table 1.
Demographic and index prescription characteristics
| |
Fingolimod |
Interferon beta-1b |
Intramuscular interferon beta-1a |
Subcutaneous interferon beta-1a |
Glatiramer acetate |
||||
|---|---|---|---|---|---|---|---|---|---|
| N=248 | N=202 | N=379 | N=355 | N=707 | |||||
| |
|
|
p-value |
|
p-value |
|
p-value |
|
p-value |
| Age Categories (%) |
|
|
0.3112 |
|
0.1516 |
|
0.0001 |
|
0.1733 |
| 18-24 |
3.2 |
2.5 |
|
3.4 |
|
2.0 |
|
1.8 |
|
| 25-34 |
10.5 |
17.8 |
|
13.5 |
|
19.2 |
|
15.6 |
|
| 35-44 |
24.6 |
23.3 |
|
28.0 |
|
33.2 |
|
27.4 |
|
| 45-54 |
37.5 |
33.7 |
|
27.2 |
|
31.6 |
|
33.1 |
|
| 55-64 |
21.0 |
18.3 |
|
22.4 |
|
10.1 |
|
17.8 |
|
| 65-74 |
3.2 |
4.5 |
|
5.0 |
|
3.9 |
|
3.7 |
|
| 75-84 |
0 |
0 |
|
0 |
|
0 |
|
0.6 |
|
| Age: mean (SD) |
46.4 (10.7) |
45.5 (11.2) |
0.4107 |
46.5 (11.5) |
0.9349 |
43.5 (10.7) |
0.0012 |
45.9 (11.1) |
0.5079 |
| Female (%) |
79.0 |
70.3 |
0.0330 |
79.7 |
0.8437 |
74.4 |
0.1850 |
76.4 |
0.3925 |
| Region (%) |
|
|
0.2046 |
|
0.0008 |
|
0.0984 |
|
0.0126 |
| Northeast |
18.2 |
17.3 |
|
31.4 |
|
23.7 |
|
29.1 |
|
| Midwest |
29.4 |
27.7 |
|
28.2 |
|
33.0 |
|
27.2 |
|
| South |
32.7 |
41.1 |
|
28.2 |
|
26.8 |
|
27.3 |
|
| West |
19.8 |
13.9 |
|
12.1 |
|
15.8 |
|
16.1 |
|
| Other/missing |
0.0 |
0.0 |
|
0.0 |
|
0.9 |
|
0.3 |
|
| Naïve to DMT treatment (%) |
38.7 |
82.7 |
<0.0001 |
82.6 |
<0.0001 |
72.4 |
<0.0001 |
83.7 |
<0.0001 |
| Specialty of prescriber: Neurologist (%) |
82.3 |
78.2 |
0.2825 |
74.7 |
0.0257 |
74.7 |
0.0270 |
77.5 |
0.1159 |
| Index medication days supply >= 90 days (%) |
0.0 |
0.5 |
0.2673 |
0.0 |
NA |
0.6 |
0.2364 |
13.6 |
<0.0001 |
| Prior authorization (yes) (%) |
56.1 |
60.4 |
0.3527 |
48.6 |
0.0662 |
46.2 |
0.0173 |
47.4 |
0.0189 |
| DMT on formulary (yes) (%) |
15.3 |
71.8 |
<0.0001 |
97.9 |
<0.0001 |
85.1 |
<0.0001 |
96.2 |
<0.0001 |
| Mail order (%) |
74.6 |
51.5 |
<0.0001 |
47.0 |
<0.0001 |
54.1 |
<0.0001 |
54.0 |
<0.0001 |
| Days’ Supply: mean (SD) |
33.3 (16.3) |
35.7 (19.5) |
0.1709 |
35.2 (18.2) |
0.2040 |
35.0 (18.4) |
0.2302 |
38.8 (21.4) |
<0.0001 |
| 30 day Co-pay: mean (SD) | 98.5 (315.5) | 101.9 (291.0) | 0.9063 | 124.1 (376.1) | 0.3588 | 88.4 (255.6) | 0.6768 | 119.2 (333.5) | 0.3944 |
P-values based on comparison with fingolimod cohort using Chi-square tests for categorical variables and Student's t-test for age, and Wilcoxon rank-sum tests were used for days' supply and copayment amount.
DMT: disease-modifying therapy. SD: standard deviation.